The Development of Transfusion-Related Acute Lung Injury for the Second Time: A New Awareness for Daratumumab?

• Main Authors: Atakan Turgutkaya, Ali Zahit Bolaman, İrfan Yavaşoğlu
• Format: Article
• Language: English
• Published: SAGE Publishing 2021-09-01
• Series: Plasmatology
• Online Access: https://doi.org/10.1177/26348535211038276

Transfusion-related acute lung injury (TRALI) is an undesired and potentially fatal complication of blood transfusion. Besides human neutrophil and leukocyte antigens of the donor blood; especially for red blood cell transfusions, nonantibody-mediated mechanisms seem responsible. Among these patients, pulmonary neutrophils have increased sensitivity to initiate TRALI. It is a very rare event for a patient to develop a second reaction. Comorbid conditions such as kidney failure and cardiovascular diseases may pose a risk. Daratumumab, an anti-CD38 monoclonal antibody, seems unrelated because it only causes indirect Coombs positivity without triggering transfusion complications. However, its role in recipient–donor interactions causing TRALI is less clear. Here, we report a relapsed multiple myeloma-diagnosed patient who developed TRALI under daratumumab treatment.